Tumors with the activating mutation V600E in BRAF account for 5–10% of colorectal cancers and are associated with a poor prognosis and a low response to epidermal growth factor receptor (EGFR; abbreviations are listed in Online Resource 1) inhibitors [1–4]. This evidence concerns the gene EGFR and colorectal cancer.